Cancer is a multifaceted global health issue and one of the leading causes of death
worldwide. In recent years, medical science has been achieved great advances in the …

Chimeric antigen receptor T-cell (CAR-T) therapies are relatively new treatments for patients
with heavily pretreated hematologic malignancies. Although these innovative therapies can …

Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …

Background Every year around the world, more than 2 million women are diagnosed with
breast cancer and genital tract cancers. However, there are rare studies comprehensively …

Background Peptic ulcer disease (PUD) affects four million people worldwide annually and
has an estimated lifetime prevalence of 5− 10% in the general population. Worldwide, there …

Background Thyroid cancer (TC) is the most prevalent malignancy of the endocrine system.
Over the past decades, TC incidence rates have been increasing. TC quality of care (QOC) …

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …

Drug resistance and poor treatment response are major obstacles to the effective treatment
of acute myeloid leukemia (AML). A deeper understanding of the mechanisms regulating …

Background Breast cancer (BC), as the top neoplasm in prevalence and mortality in females,
imposes a heavy burden on health systems. Evaluation of quality of care and management …

Hematologic neoplasms represent 6.5% of all cancers worldwide. They are characterized by
the uncontrolled growth of hematopoietic and lymphoid cells and a decreased immune …